Iradimed (NASDAQ:IRMD) Releases FY 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.710-1.810 for the period, compared to the consensus estimate of 1.750. The company issued revenue guidance of $78.0 million-$82.0 million, compared to the consensus revenue estimate of $80.7 million. Iradimed also updated its Q1 2025 guidance to 0.390-0.430 EPS.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Iradimed Price Performance

Shares of NASDAQ IRMD traded down $4.58 on Thursday, hitting $55.90. The company’s stock had a trading volume of 69,002 shares, compared to its average volume of 40,757. Iradimed has a 12-month low of $40.18 and a 12-month high of $63.29. The company has a market capitalization of $708.25 million, a price-to-earnings ratio of 38.33 and a beta of 0.82. The stock has a 50 day moving average of $57.16 and a 200-day moving average of $52.02.

Iradimed (NASDAQ:IRMD) last announced its quarterly earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.05). Iradimed had a net margin of 26.12% and a return on equity of 23.99%. Sell-side analysts expect that Iradimed will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling

In other Iradimed news, CFO John Glenn sold 2,500 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at $237,470.94. This trade represents a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 37.10% of the stock is owned by company insiders.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.